Impact of Augmented Reality During Robot-assisted Radical Prostatectomy

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Sep 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of augmented reality (AR) technology during robot-assisted surgery for prostate cancer. The goal is to see if this advanced technology can help surgeons more accurately preserve important nerves during the procedure, which could lead to better recovery of erectile function and lower rates of cancer returning after surgery. Researchers hope that using AR will result in fewer positive surgical margins, meaning the cancer is less likely to remain after the operation.

To participate in this trial, men aged 18 and older with untreated, biopsy-proven prostate cancer may be eligible if they have low to intermediate risk based on specific medical criteria. Participants will receive detailed information about the trial and must provide written consent. If selected, they can expect to undergo the AR-assisted surgery and will be monitored for their recovery and any side effects. This trial is currently recruiting participants, and it's an important step in validating the use of augmented reality in prostate cancer surgery.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Untreated, biopsy-proven adenocarcinoma of the prostate Age ≥18 years
• European Association of Urology (EAU) low or intermediate risk prostate cancer:
• • PSA≤20 ng/ml
• • cT≤2b
• • International Society for Urological Pathology \[ISUP\] grade group≤III Written informed consent provided for participation in the trial International Index of Erectile Function-5 (IIEF-5)≥20 No contraindications for multiparametric magnetic resonance imaging (mpMRI)
• Exclusion Criteria:
• • Any prior therapy for prostate cancer
• European Association of Urology (EAU) high risk prostate cancer:
• • PSA\>20 ng/ml or
• • cT\>2b or
• • ISUP grade group\>III International Index of Erectile Function-5 (IIEF-5)\<20 Prostate cancer with sarcomatoid or spindle cell or neuroendocrine small cell components Morbidity that would limit compliance with study protocols Controindications to perform mpMRI